Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoadjuvant Therapy \High Risk Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × proxalutamide × Clear all
NCT03899467 2024-02-12

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Completed
61 enrolled 12 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT05076851 2021-10-13

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy(ADT)for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
2 enrolled
Genitourinary

Neoadjuvant Therapy \High Risk Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡